Solace Therapeutics
Prior to this, he served as VP of R&D for Interlace Medical since inception through January 2011 and continued on as VP of R&D for Hologic post acquisition through 2013. Albert has over 20 years experience and a proven track record in technology and product development of minimally invasive medical devices from concept to commercialization. Prior to Interlace, he was director of R&D for Neurotechnologies at Codman, a J&J company, where he managed a $3M+ budget and successfully launched three new products in electrosurgery, neuro monitoring and biologics markets. Prior to Codman, he spent 11 years in Corporate Technology Group at Boston Scientific Corporation as R&D/Program Manager managing new product development projects with budgets ranging from $2M to $20M. During his time at Boston Scientific Corporation, he co-founded two internal startups which led to the formation of two new divisions in Neurointervention and Endovascular businesses. He has 15 issued patents on proprietary technology platforms for multiple medical devices with annual revenues over $100M. Prior to Boston Scientific Corporation, he was an R&D engineer for Kendall Company.
This person is not in any offices
Solace Therapeutics
Solace Therapeutics is an emerging medical device company focused on the development of non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), Solace is dedicated to improving the patient’s quality of life by eliminating side effects typically associated with current drug and surgical therapies.